Yuichiro Shindo1, Shinji Sato2, Eiichi Maruyama2, Takamasa Ohashi2, Masahiro Ogawa2, Naozumi Hashimoto3, Kazuyoshi Imaizumi3, Tosiya Sato4, Yoshinori Hasegawa3. 1. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address: yshindo@med.nagoya-u.ac.jp. 2. Department of Respiratory Medicine, Handa City Hospital, Aichi, Japan. 3. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. 4. Department of Biostatistics, Kyoto University School of Public Health, Kyoto, Japan.
Abstract
BACKGROUND: Health-care-associated pneumonia (HCAP) is a relatively new concept. Epidemiologic studies are limited, and initial empirical antibiotic treatment is still under discussion. This study aimed to reveal the differences in mortality and pathogens between HCAP and community-acquired pneumonia (CAP) in each severity class, and to clarify the strategy for the treatment of HCAP. METHODS: We conducted a retrospective observational study of patients with HCAP and CAP who were hospitalized between November 2005 and January 2007, and compared baseline characteristics, severity, pathogen distribution, antibiotic regimens, and outcomes. In each severity class (mild, moderate, and severe) assessed using the A-DROP scoring system (ie, age, dehydration, respiratory failure, orientation disturbance, and low BP), we investigated the in-hospital mortality and occurrence of potentially drug-resistant (PDR) pathogens. RESULTS: A total of 371 patients (141 HCAP patients, 230 CAP patients) were evaluated. The proportion of patients in the severe class was higher in the HCAP patients than in CAP patients. In the moderate class, the in-hospital mortality proportion of HCAP patients was significantly higher than that of CAP patients (11.1% vs 1.9%, respectively; p = 0.008). In moderate-class patients in whom pathogens were identified, PDR pathogens were isolated more frequently from HCAP patients than from CAP patients (22.2% vs 1.9%, respectively; p = 0.002). The occurrence of PDR pathogens was associated with initial treatment failure and inappropriate initial antibiotic treatment. CONCLUSIONS: The present study provides additional evidence that HCAP should be distinguished from CAP, and suggests that the therapeutic strategy for HCAP in the moderate class holds the key to improving mortality. Physicians may need to consider PDR pathogens in selecting the initial empirical antibiotic treatment of HCAP.
BACKGROUND:Health-care-associated pneumonia (HCAP) is a relatively new concept. Epidemiologic studies are limited, and initial empirical antibiotic treatment is still under discussion. This study aimed to reveal the differences in mortality and pathogens between HCAP and community-acquired pneumonia (CAP) in each severity class, and to clarify the strategy for the treatment of HCAP. METHODS: We conducted a retrospective observational study of patients with HCAP and CAP who were hospitalized between November 2005 and January 2007, and compared baseline characteristics, severity, pathogen distribution, antibiotic regimens, and outcomes. In each severity class (mild, moderate, and severe) assessed using the A-DROP scoring system (ie, age, dehydration, respiratory failure, orientation disturbance, and low BP), we investigated the in-hospital mortality and occurrence of potentially drug-resistant (PDR) pathogens. RESULTS: A total of 371 patients (141 HCAPpatients, 230 CAP patients) were evaluated. The proportion of patients in the severe class was higher in the HCAPpatients than in CAP patients. In the moderate class, the in-hospital mortality proportion of HCAPpatients was significantly higher than that of CAP patients (11.1% vs 1.9%, respectively; p = 0.008). In moderate-class patients in whom pathogens were identified, PDR pathogens were isolated more frequently from HCAPpatients than from CAP patients (22.2% vs 1.9%, respectively; p = 0.002). The occurrence of PDR pathogens was associated with initial treatment failure and inappropriate initial antibiotic treatment. CONCLUSIONS: The present study provides additional evidence that HCAP should be distinguished from CAP, and suggests that the therapeutic strategy for HCAP in the moderate class holds the key to improving mortality. Physicians may need to consider PDR pathogens in selecting the initial empirical antibiotic treatment of HCAP.
Authors: M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij Journal: Clin Microbiol Infect Date: 2011-11 Impact factor: 8.067
Authors: Alan E Gross; Trevor C Van Schooneveld; Keith M Olsen; Mark E Rupp; Thu Hong Bui; Elsie Forsung; Andre C Kalil Journal: Antimicrob Agents Chemother Date: 2014-06-23 Impact factor: 5.191
Authors: Marco Falcone; Salvatore Corrao; Mario Venditti; Pietro Serra; Giuseppe Licata Journal: Intern Emerg Med Date: 2011-01-20 Impact factor: 3.397
Authors: Marco Falcone; Salvatore Corrao; Giuseppe Licata; Pietro Serra; Mario Venditti Journal: Intern Emerg Med Date: 2012-06-12 Impact factor: 3.397
Authors: Manisha Juthani-Mehta; Peter H Van Ness; Joanne McGloin; Stephanie Argraves; Shu Chen; Peter Charpentier; Laura Miller; Kathleen Williams; Diane Wall; Dorothy Baker; Mary Tinetti; Peter Peduzzi; Vincent J Quagliarello Journal: Clin Infect Dis Date: 2014-12-16 Impact factor: 9.079